STATE-OF-THE-ART PAPER
Regadenoson: A New Myocardial Stress Agent
Wael Al Jaroudi, MD* and
Ami E. Iskandrian, MD
Division of Cardiovascular Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama
Manuscript received January 22, 2009;
revised manuscript received March 10, 2009,
accepted April 26, 2009.
* Reprint requests and correspondence: Dr. Wael Al Jaroudi, 701 19th Street, LHRB 306, Birmingham, Alabama 35294 (Email: waljaroudi{at}cardmail.dom.uab.edu).
Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A2A agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A2A agonist.
Key Words: adenosine regadenoson myocardial perfusion imaging single-photon emission computed tomography stress testing
|
Abbreviations and Acronyms
| | COPD = chronic obstructive pulmonary disease | | FDA = Food and Drug Administration | | FEV1
= forced expiratory volume (1 s) | | LV = left ventricle/ventricular | | MBF = myocardial blood flow | | MPI = myocardial perfusion imaging |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A27.
[Full Text]
[PDF]
|